RxRevu

At RxRevu we believe in improving the value of healthcare through informed, consistent prescription decisions. We also believe that lasting changes require a dedicated intention and aligned effort, and we are committed to investing in the future of healthcare. We leverage Prescription Decision Support (PDS) to deliver real-time, patient-specific cost information, electronic prior authorization, and therapeutic alternatives at the point of care. By doing so, we enable shared decisions between providers and patients, help patients get the right medication the first time, and remove friction from the point of care to fulfillment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HEALTH TECHNOLOGY

MHN INTEGRATES PATIENT DATA WITH EMR SYSTEMS TO ENABLE BETTER CARE

Medical Home Network | January 12, 2022

news image

Medical Home Network (MHN) is helping healthcare providers have more informed conversations with patients by enabling easy access to patient data in one place. With a timely and comprehensive view of patient information, providers can make more informed decisions and ultimately deliver better care. MHN is integrating patient data across different electronic medical record systems (EMRs) for 13 providers and more than 160,000 Medicaid safety net patients, making data accessible to pr...

Read More

BIO PRODUCTS LABORATORY ANNOUNCES LAUNCH OF ALBUMINEX® 5% AND ALBUMINEX® 25% WITH SUPPLY IMMEDIATELY AVAILABLE IN THE UNITED STATES

Bio Products Laboratory | May 29, 2020

news image

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, today announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection, with supply immediately available. ALBUMINEX 5% and ALBUMINEX 25% are approved by the US Food and Drug Administration for the treatment of hypovole...

Read More

FUTURE OF HEALTHCARE

HOUSE RX SECURES $30 MILLION IN FINANCING TO IMPROVE THE SPECIALTY PHARMACY EXPERIENCE FOR PATIENTS AND THEIR CARE TEAMS

House Rx | March 15, 2022

news image

House Rx, a health technology platform focused on improving affordability and patient access to specialty medications, announced it has secured $25 million in Series A financing led by Bessemer Venture Partners, bringing total funding to $30 million. House Rx's technology platform and pharmacy service enable specialty practices to offer medically-integrated dispensing, which means patients can receive both their physician and pharmacy care from one team, collaborating on a unifi...

Read More

HEALTH TECHNOLOGY

NVIDIA LAUNCHES UK’S MOST POWERFUL SUPERCOMPUTER, FOR RESEARCH IN AI AND HEALTHCARE

NVIDIA | July 07, 2021

news image

NVIDIA today officially launched Cambridge-1, the United Kingdom’s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country’s world-leading life sciences industry. Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy’s and ...

Read More
news image

HEALTH TECHNOLOGY

MHN INTEGRATES PATIENT DATA WITH EMR SYSTEMS TO ENABLE BETTER CARE

Medical Home Network | January 12, 2022

Medical Home Network (MHN) is helping healthcare providers have more informed conversations with patients by enabling easy access to patient data in one place. With a timely and comprehensive view of patient information, providers can make more informed decisions and ultimately deliver better care. MHN is integrating patient data across different electronic medical record systems (EMRs) for 13 providers and more than 160,000 Medicaid safety net patients, making data accessible to pr...

Read More
news image

BIO PRODUCTS LABORATORY ANNOUNCES LAUNCH OF ALBUMINEX® 5% AND ALBUMINEX® 25% WITH SUPPLY IMMEDIATELY AVAILABLE IN THE UNITED STATES

Bio Products Laboratory | May 29, 2020

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina, and worldwide headquarters and manufacturing facilities in Elstree, UK, today announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection, with supply immediately available. ALBUMINEX 5% and ALBUMINEX 25% are approved by the US Food and Drug Administration for the treatment of hypovole...

Read More
news image

FUTURE OF HEALTHCARE

HOUSE RX SECURES $30 MILLION IN FINANCING TO IMPROVE THE SPECIALTY PHARMACY EXPERIENCE FOR PATIENTS AND THEIR CARE TEAMS

House Rx | March 15, 2022

House Rx, a health technology platform focused on improving affordability and patient access to specialty medications, announced it has secured $25 million in Series A financing led by Bessemer Venture Partners, bringing total funding to $30 million. House Rx's technology platform and pharmacy service enable specialty practices to offer medically-integrated dispensing, which means patients can receive both their physician and pharmacy care from one team, collaborating on a unifi...

Read More
news image

HEALTH TECHNOLOGY

NVIDIA LAUNCHES UK’S MOST POWERFUL SUPERCOMPUTER, FOR RESEARCH IN AI AND HEALTHCARE

NVIDIA | July 07, 2021

NVIDIA today officially launched Cambridge-1, the United Kingdom’s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country’s world-leading life sciences industry. Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy’s and ...

Read More